Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cybin Inc. stock logo
CYBN
Cybin
$8.15
-5.0%
$7.52
$4.81
$13.88
$187.65M0.68268,517 shs182,543 shs
enGene Holdings Inc. stock logo
ENGN
enGene
$3.66
+1.9%
$3.64
$2.65
$11.00
$187.03M-0.4129,396 shs67,356 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.69
-1.1%
$12.51
$5.22
$27.38
$159.77M0.43153,270 shs1.62 million shs
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
$1.47
+1.4%
$1.85
$1.35
$4.40
$32.56M1.329,357 shs111,270 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cybin Inc. stock logo
CYBN
Cybin
0.00%+4.76%+2.39%+28.55%+2,108.67%
enGene Holdings Inc. stock logo
ENGN
enGene
0.00%+16.19%-5.43%-18.30%-61.19%
Lifevantage Corporation stock logo
LFVN
Lifevantage
0.00%+1.28%-1.48%-12.96%+97.66%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
0.00%-4.55%-23.44%-16.95%+146,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cybin Inc. stock logo
CYBN
Cybin
2.6601 of 5 stars
3.60.00.00.02.50.81.3
enGene Holdings Inc. stock logo
ENGN
enGene
2.771 of 5 stars
3.53.00.00.01.72.50.6
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.028 of 5 stars
3.50.01.72.72.61.71.3
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cybin Inc. stock logo
CYBN
Cybin
3.25
Buy$86.00955.21% Upside
enGene Holdings Inc. stock logo
ENGN
enGene
3.00
Buy$23.29536.22% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50140.35% Upside
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest RNTX, LFVN, CYBN, and ENGN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/13/2025
Cybin Inc. stock logo
CYBN
Cybin
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/29/2025
enGene Holdings Inc. stock logo
ENGN
enGene
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.00
(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/A$10.83 per shareN/A
enGene Holdings Inc. stock logo
ENGN
enGene
N/AN/AN/AN/A$5.35 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.80$0.88 per share14.39$2.05 per share6.19
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/A$0.45 per share3.28$0.43 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cybin Inc. stock logo
CYBN
Cybin
-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/A
enGene Holdings Inc. stock logo
ENGN
enGene
-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.39N/A4.12%34.67%15.24%8/27/2025 (Estimated)
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$62.88M-$2.86N/AN/AN/AN/A-86.07%-31.11%N/A

Latest RNTX, LFVN, CYBN, and ENGN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/10/2025Q2 2025
enGene Holdings Inc. stock logo
ENGN
enGene
-$0.4768-$0.51-$0.0332-$0.51N/AN/A
5/15/2025Q1 2025
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
-$0.21-$0.25-$0.04-$0.25N/AN/A
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
4/7/2025Q4 2024
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/A-$0.26N/A-$1.89N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cybin Inc. stock logo
CYBN
Cybin
N/AN/AN/AN/AN/A
enGene Holdings Inc. stock logo
ENGN
enGene
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.42%N/A26.09%3 Years
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/AN/AN/AN/AN/A

Latest RNTX, LFVN, CYBN, and ENGN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cybin Inc. stock logo
CYBN
Cybin
N/A
24.24
24.24
enGene Holdings Inc. stock logo
ENGN
enGene
0.09
12.66
12.66
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
N/A
1.39
1.39

Institutional Ownership

CompanyInstitutional Ownership
Cybin Inc. stock logo
CYBN
Cybin
17.94%
enGene Holdings Inc. stock logo
ENGN
enGene
64.16%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
90.89%

Insider Ownership

CompanyInsider Ownership
Cybin Inc. stock logo
CYBN
Cybin
15.00%
enGene Holdings Inc. stock logo
ENGN
enGene
10.40%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
5.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cybin Inc. stock logo
CYBN
Cybin
5023.02 million17.96 millionNot Optionable
enGene Holdings Inc. stock logo
ENGN
enGene
3151.10 million45.79 millionN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
Rein Therapeutics Inc. stock logo
RNTX
Rein Therapeutics
922.15 million21.02 millionN/A

Recent News About These Companies

RNTX - Rein Therapeutics Inc Dividends - Morningstar
RNTX Rein Therapeutics Inc.

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cybin stock logo

Cybin NYSE:CYBN

$8.15 -0.43 (-5.01%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$8.27 +0.12 (+1.47%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

enGene stock logo

enGene NASDAQ:ENGN

$3.66 +0.07 (+1.95%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$3.66 -0.01 (-0.14%)
As of 06/27/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.69 -0.14 (-1.09%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$12.79 +0.10 (+0.79%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Rein Therapeutics stock logo

Rein Therapeutics NASDAQ:RNTX

$1.47 +0.02 (+1.38%)
As of 06/27/2025 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.